Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position?

CRISPR Therapeutics is the second-largest holding in Cathie Wood's ARK Innovation ETF, signaling concentrated ETF exposure to the stock. Incoming clinical trial data this year are highlighted as potential catalysts that could drive significant upside if positive, making the name a speculative, event-driven trade.

Analysis

CRISPR Therapeutics is the second-largest holding in Cathie Wood's ARK Innovation ETF, signaling concentrated ETF exposure to the stock. Incoming clinical trial data this year are highlighted as potential catalysts that could drive significant upside if positive, making the name a speculative, event-driven trade.